Company Overview and News

 
Up Cannabis’ Niagara Facility Licensed for Cultivation

2018-04-02 globenewswire
TORONTO, April 02, 2018 (GLOBE NEWSWIRE) -- Newstrike Resources Ltd. (TSX-V:HIP) ("Newstrike" or the "Company"), is pleased to announce that its wholly-owned subsidiary and licensed producer of cannabis, Up Cannabis Inc. (“Up Cannabis”), has received a producer’s licence to cultivate (“Licence”) in respect of its 160,000 sq. ft. automated greenhouse site in the Niagara region (the “Niagara Facility”).

 
Former mining companies turning to pot to strike gold

2018-03-19 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com

1
Pot producer Aurora gets final regulatory nod for CanniMed purchase

2018-02-28 reuters
(Reuters) - Canada’s No.2 marijuana producer Aurora Cannabis Inc (ACB.TO) on Wednesday received final regulatory approval for the purchase of smaller rival CanniMed Therapeutics Inc (CMED.TO), which would make it the world’s most valuable weed producer.

 
Greenhouse growers take chance on cannabis in push for green

2018-02-01 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com

 
From weed to wages: Ontario marijuana producers hit by minimum pay rate hike

2018-01-29 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com

 
From weed to wages: Ontario marijuana producers hit by minimum pay rate hike

2018-01-29 cbc.ca
It's not just coffee chains and restaurants under pressure from Ontario's minimum wage hike — marijuana companies say the higher provincial pay rate is driving up the cost to produce and sell cannabis products as well.

 
Aurora Cannabis Acquires CanniMed Therapeutics

2018-01-25 editors.aws.marketrealist
The marijuana space is already heating up with mergers and acquisitions ahead of recreational marijuana legalization expected in Canada later this year.

 
BRIEF-Newstrike Resources Announces Upsize Of Previously Announced Bought Deal Financing To $80 Million

2018-01-24 reuters
* NEWSTRIKE RESOURCES - ENTERED REVISED AGREEMENT TO INCREASE SIZE OF PREVIOUSLY ANNOUNCED BOUGHT DEAL FINANCING TO $80 MILLION AGGREGATE GROSS PROCEEDS Source text for Eikon: Further company coverage:

 
Newstrike Resources Ltd. Announces Upsize of Previously Announced Bought Deal Financing to $80 million

2018-01-24 marketwired
Newstrike Resources Ltd. (TSX VENTURE:HIP) ("Newstrike" or the "Company") is pleased to announce that the Company has entered into a revised agreement with a syndicate of underwriters co-led by INFOR Financial Inc. and Cormark Securities Inc. (collectively, the "Underwriters"), to increase the size of its previously announced bought deal financing to $80,005,200 aggregate gross proceeds (the "Offering"), representing 60,610,000 Units of the Company (the "Units"), at a price of $1.

 
BRIEF-Newstrike Resources Announces $50 Million Bought Deal Financing

2018-01-24 reuters
* NEWSTRIKE RESOURCES LTD - ENTERED AGREEMENT WITH UNDERWRITERS WHERE UNDERWRITERS AGREED TO BUY 39 MILLION UNITS OF CO ON A BOUGHT DEAL BASIS

 
UPDATE 3-Canada's Aurora Cannabis to buy smaller rival to create No. 2 producer

2018-01-24 reuters
(Reuters) - Canada’s second-biggest marijuana producer Aurora Cannabis Inc has agreed to buy smaller rival CanniMed Therapeutics Inc for C$1.1 billion ($852 million), creating the globe’s largest weed producer by market value.

 
Newstrike Resources Ltd. Announces $50 Million Bought Deal Financing

2018-01-24 marketwired
Newstrike Resources Ltd. (TSX VENTURE:HIP) ("Newstrike" or the "Company") is pleased to announce that it has entered into an agreement with a syndicate of underwriters (the "Underwriters") co-led by INFOR Financial Inc. and Cormark Securities Inc. pursuant to which the Underwriters have agreed to purchase 39,000,000 units (the "Units") of the Company on a "bought deal" basis pursuant to a short form prospectus to be filed, subject to all required regulatory approvals, at a price per Unit of $1.

 
BRIEF-Newstrike Agreed With CanniMed To Terminate Previously Announced Agreement, Dated Nov 17

2018-01-24 reuters
* NEWSTRIKE TO RECEIVE $14.1 MILLION AND STRENGTHEN BALANCE SHEET WITH DEBT CONVERSION FOLLOWING TERMINATION OF ARRANGEMENT AGREEMENT

 
Newstrike to Receive $14.1 Million and Strengthen Balance Sheet with Debt Conversion Following Termination of Arrangement Agreement

2018-01-24 marketwired
CanniMed agrees to exercise all warrants and fully convert secured debenture in addition to payment of $9.5 million Break Fee

 
Newstrike Resources Ltd. Provides Update on Arrangement Transaction

2018-01-23 marketwired
TORONTO, ONTARIO--(Marketwired - Jan. 23, 2018) - Newstrike Resources Ltd. ("Newstrike" or the "Company") (TSX VENTURE:HIP) announces that pending the results of discussions among Aurora Cannabis Inc. ("Aurora") and CanniMed Therapeutics Inc. ("CanniMed"), it has adjourned the hearing for the final court order in connection with the plan of arrangement relating to the acquisition by CanniMed of Newstrike (the "Plan of Arrangement"), as specified in the Company's management information circular dated December 12, 2017 (the "Management Information Circular"), available on SEDAR at www.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...